Novacyt S.A. Court sanction of the Scheme of Arrangement (7518L)
September 07 2023 - 6:22AM
UK Regulatory
TIDMNCYT
RNS Number : 7518L
Novacyt S.A.
07 September 2023
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Court sanction of the Scheme of Arrangement
Paris, France and Eastleigh, UK - 7 September 2023 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, notes today's announcement by Yourgene Health
plc ("Yourgene"), in relation to the recommended cash offer made by
Novacyt UK Holdings Limited ("Novacyt UK"), a wholly-owned
subsidiary of Novacyt, for the entire issued and to be issued share
capital of Yourgene announced on 3 July 2023 (the "Acquisition"),
which is to be effected by means of a Court-sanctioned scheme of
arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
A circular in relation to the Scheme was published by Yourgene on
27 July 2023 (the "Scheme Document").
Capitalised terms used in this announcement shall, unless
otherwise defined, have the same meaning as set out in the Scheme
Document.
Further to the announcement made by Yourgene on 17 August 2023
in relation to the passing of the Resolutions required to approve
and implement the Scheme at the Court Meeting and the General
Meeting, Yourgene has announced that at the Court Sanction Hearing
held earlier today the Court issued the Court Order sanctioning the
Scheme.
There has been no change to the expected timetable of principal
events for the Acquisition set out in the Scheme Document.
Yourgene's full announcement regarding the Court Sanction Hearing,
including detailed next steps and timetable, can be found here:
https://polaris.brighterir.com/public/yourgenehealth/news/rns/story/rmv3p9r
Contacts
Novacyt SA +44 (0)23 8074 8830
James Wakefield, Non-Executive
Chairman
James McCarthy, Acting Chief Executive
Officer
Numis (Financial Adviser and Joint Broker
to Novacyt and Financial Adviser to Novacyt
UK) +44 (0)20 7260 1000
Freddie Barnfield / Stuart Ord / Duncan
Monteith / Jack McLaren
SP Angel Corporate Finance LLP (Nominated
Adviser and Joint Broker to Novacyt) +44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate
Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Allegra Finance (French Listing Sponsor) +33 (1) 42 22 10 10
Rémi Durgetto / Yannick Petit r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780
Stephanie Cuthbert / Anna Dunphy novacyt@walbrookpr.com
/ Phillip Marriage
About Novacyt Group
Novacyt is an international diagnostics business delivering a
broad portfolio of in vitro and molecular diagnostic tests for a
wide range of infectious diseases, enabling faster, more accurate,
accessible testing to improve healthcare outcomes. The Company
provides customers with a seamless sample-to-result workflow using
its integrated and scalable instrumentation/solutions. The Company
specialises in the design, manufacture, and supply of real-time PCR
kits, reagents and a full range of laboratory and qPCR
instrumentation for molecular biology research and clinical use.
Novacyt offers one of the world's most varied and comprehensive
range of qPCR assays, covering human, veterinary, biodefence,
environmental, agriculture and food testing.
Novacyt is headquartered in Vélizy in France with offices in
Stokesley and Eastleigh, UK, and is listed on the London Stock
Exchange's AIM market ("NCYT") and on the Paris Stock Exchange
Euronext Growth ("ALNOV").
For more information, please refer to the website:
www.novacyt.com
About Yourgene Health
Yourgene Health is an international integrated technologies and
services business, enabling the delivery of genomic medicine. The
Group works in partnership with global leaders in DNA technology to
advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic and screening solutions,
for reproductive health and precision medicine. The Group's
portfolio of in vitro diagnostic products includes non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests and DPYD genotyping assays.
Building on our expertise in genomic technology, Yourgene's
Ranger(R) Technology offers next generation size selection with a
range of sample preparation platforms for dynamic target
enrichment. Ranger(R) Technology can be utilised to improve
workflows and performance in multiple applications including NIPT,
oncology, infectious disease testing and gene synthesis.
Yourgene Genomic Services offers a clinical service from UK and
Taiwan focusing on precision medicine and reproductive health,
including NIPT.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN".
For more information visit https://yourgenehealth.com/ and
follow us on twitter @Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
SOABBGDCCBGDGXR
(END) Dow Jones Newswires
September 07, 2023 07:22 ET (11:22 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2024 to Jun 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From Jun 2023 to Jun 2024